Formulation and Evaluation of Lipidized Imiquimod as an Effective Adjuvant.
ACS Infect Dis
; 9(2): 378-387, 2023 02 10.
Article
em En
| MEDLINE
| ID: mdl-36688646
ABSTRACT
Adjuvants are essential for the induction of robust immune responses against vaccine antigens. Small-molecule TLR7 agonists hold high potential for this purpose. In this communication, imiquimod (IMQ) bearing a cholesterol lipid moiety derivative, IMQ-Chol, was designed and synthesized as a vaccine adjuvant, which could release parent IMQ molecules in aqueous conditions via amide bond hydrolysis. We performed a series of immunological evaluations by cooperating with the inactivated foot-and-mouth disease virus (FMDV). All of the results confirmed that IMQ-Chol could stimulate the body for a prolonged time to produce strong humoral and cellular immunity with a balanced Th1/Th2 immune response through a TLR7-related MAPK pathway. In addition, the results of the proof-of-concept vaccine indicated IMQ-Chol had a good effect on preventing and treating FMD in pigs.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vírus da Febre Aftosa
/
Receptor 7 Toll-Like
Limite:
Animals
Idioma:
En
Revista:
ACS Infect Dis
Ano de publicação:
2023
Tipo de documento:
Article